Markian M. Stec

Publications by Year

Research Areas

PI3K/AKT/mTOR signaling in cancer, Ion Channels and Receptors, Biochemical Analysis and Sensing Techniques, Protein Kinase Regulation and GTPase Signaling, Pain Mechanisms and Treatments

Most-Cited Works

• → Novel Vanilloid Receptor-1 Antagonists: 2. Structure−Activity Relationships of 4-Oxopyrimidines Leading to the Selection of a Clinical Candidate(2007)98 cited
• → Design and Synthesis of Peripherally Restricted Transient Receptor Potential Vanilloid 1 (TRPV1) Antagonists(2008)62 cited
• → Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511(2012)50 cited
• → Structure–Activity Relationships of Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Investigations of Various 6,5-Heterocycles to Improve Metabolic Stability(2011)44 cited
• → Novel Vanilloid Receptor-1 Antagonists: 1. Conformationally Restricted Analogues oftrans-Cinnamides(2007)42 cited
• → Synthesis of novel melanocortin 4 receptor agonists and antagonists containing a succinamide core(2003)33 cited
• → Small Molecule Disruptors of the Glucokinase–Glucokinase Regulatory Protein Interaction: 2. Leveraging Structure-Based Drug Design to Identify Analogues with Improved Pharmacokinetic Profiles(2014)24 cited
• → The imidazo[1,2-a]pyridine ring system as a scaffold for potent dual phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors(2015)20 cited
• → Melanocortin subtype-4 receptor agonists containing a piperazine core with substituted aryl sulfonamides(2005)19 cited
• → Substituted aryl pyrimidines as potent and soluble TRPV1 antagonists(2008)11 cited